113 related articles for article (PubMed ID: 26169922)
1. Pancreatic cancer: Targeting KRAS and the vitamin D receptor via microtubules.
Basseville A; Bates S; Fojo T
Nat Rev Clin Oncol; 2015 Aug; 12(8):442-4. PubMed ID: 26169922
[No Abstract] [Full Text] [Related]
2. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.
Witkiewicz AK; McMillan EA; Balaji U; Baek G; Lin WC; Mansour J; Mollaee M; Wagner KU; Koduru P; Yopp A; Choti MA; Yeo CJ; McCue P; White MA; Knudsen ES
Nat Commun; 2015 Apr; 6():6744. PubMed ID: 25855536
[TBL] [Abstract][Full Text] [Related]
3. Identification of germline and somatic mutations in pancreatic adenosquamous carcinoma using whole exome sequencing.
Ma H; Song B; Guo S; Li G; Jin G
Cancer Biomark; 2020; 27(3):389-397. PubMed ID: 31958074
[TBL] [Abstract][Full Text] [Related]
4. Tracking the Clonal Evolution of Adenosquamous Carcinoma, a Rare Variant of Intraductal Papillary Mucinous Neoplasm of the Pancreas.
Matsuzaka S; Karasaki H; Ono Y; Ogata M; Oikawa K; Tamakawa S; Chiba S; Muraki M; Yokochi T; Funakoshi H; Kono T; Nagashima K; Mizukami Y
Pancreas; 2016 Jul; 45(6):915-8. PubMed ID: 27295533
[TBL] [Abstract][Full Text] [Related]
5. BCL10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens.
Hosoda W; Sasaki E; Murakami Y; Yamao K; Shimizu Y; Yatabe Y
Pathol Int; 2013 Mar; 63(3):176-82. PubMed ID: 23530562
[TBL] [Abstract][Full Text] [Related]
6. Genomic signatures of pancreatic adenosquamous carcinoma (PASC).
Fang Y; Su Z; Xie J; Xue R; Ma Q; Li Y; Zhao Y; Song Z; Lu X; Li H; Peng C; Bai F; Shen B
J Pathol; 2017 Oct; 243(2):155-159. PubMed ID: 28722109
[TBL] [Abstract][Full Text] [Related]
7. Homeobox gene CDX2 inhibits human pancreatic cancer cell proliferation by down-regulating cyclin D1 transcriptional activity.
Takahashi K; Hirano F; Matsumoto K; Aso K; Haneda M
Pancreas; 2009 Jan; 38(1):49-57. PubMed ID: 19106744
[TBL] [Abstract][Full Text] [Related]
8. Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell targeting of mutant Kras in transgenic mice.
Grippo PJ; Nowlin PS; Demeure MJ; Longnecker DS; Sandgren EP
Cancer Res; 2003 May; 63(9):2016-9. PubMed ID: 12727811
[TBL] [Abstract][Full Text] [Related]
9. Translational research in pancreatic cancer: KRAS and beyond.
Boeck S; Ormanns S; Haas M; Bächmann S; Laubender RP; Siveke JT; Jung A; Kirchner T; Heinemann V
Pancreas; 2014 Jan; 43(1):150-2. PubMed ID: 24326376
[No Abstract] [Full Text] [Related]
10. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
11. Role of radiation therapy in the management of locally advanced pancreatic cancer.
Aref A; Berri R
J Clin Oncol; 2012 May; 30(13):1564-5; author reply 1566-7. PubMed ID: 22412127
[No Abstract] [Full Text] [Related]
12. Recent advances in genomic profiling of adenosquamous carcinoma of the pancreas.
Marcus R; Maitra A; Roszik J
J Pathol; 2017 Nov; 243(3):271-272. PubMed ID: 28816351
[TBL] [Abstract][Full Text] [Related]
13. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma.
Hashimoto D; Arima K; Yokoyama N; Chikamoto A; Taki K; Inoue R; Kaida T; Higashi T; Nitta H; Ohmuraya M; Hirota M; Beppu T; Baba H
Pancreas; 2016 Sep; 45(8):1111-4. PubMed ID: 26967456
[TBL] [Abstract][Full Text] [Related]
15. FNA smears of pancreatic ductal adenocarcinoma are superior to formalin-fixed paraffin-embedded tissue as a source of DNA: Comparison of targeted KRAS amplification and genotyping in matched preresection and postresection samples.
Hartley CP; Mahajan AM; Selvaggi SM; Rehrauer WM
Cancer Cytopathol; 2017 Nov; 125(11):838-847. PubMed ID: 29024530
[TBL] [Abstract][Full Text] [Related]
16. Adenosquamous carcinoma of the pancreas: preoperative diagnosis and molecular alterations.
Murakami Y; Yokoyama T; Yokoyama Y; Kanehiro T; Uemura K; Sasaki M; Morifuji M; Sueda T
J Gastroenterol; 2003; 38(12):1171-5. PubMed ID: 14714256
[TBL] [Abstract][Full Text] [Related]
17. Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions.
Nagawkar SS; Abu-Funni S; Simon E; Bick T; Prinz E; Sabo E; Ben-Izhak O; Hershkovitz D
Pancreas; 2016 Jul; 45(6):876-81. PubMed ID: 26646269
[TBL] [Abstract][Full Text] [Related]
18. Characterization of KRAS Mutation in Acinar and Langerhans Islet Cells of Patients With Pancreatic Ductal Adenocarcinoma.
Wang Z; Zhang C; Nagee K; Mohammadi A; Monteiro C
Pancreas; 2016 Mar; 45(3):337-41. PubMed ID: 26474433
[TBL] [Abstract][Full Text] [Related]
19. Kras, Pten, NF-κB, and inflammation: dangerous liaisons.
Chiao PJ; Ling J
Cancer Discov; 2011 Jul; 1(2):103-5. PubMed ID: 22586351
[TBL] [Abstract][Full Text] [Related]
20. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes.
Immervoll H; Hoem D; Kugarajh K; Steine SJ; Molven A
Virchows Arch; 2006 Jun; 448(6):788-96. PubMed ID: 16598499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
